Innovators are using increasingly complicated tactics in the high-stakes game of keeping biosimilars at bay to ensure their brand-name medicines can keep hauling in the cash for as long as possible.
In the high-stakes game of defending blockbuster biologics from biosimilar competition, innovators are relying on labyrinthine defenses to ensure they can keep hauling in the cash from their products for as long as possible.
Indeed, while the ongoing litigation over the Biologics Price Competition and Innovation Act (BPCIA) is expected to eventually iron out...
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
